Anixa Biosciences (NASDAQ:ANIX) Director Lewis Titterton Jr Purchases 49,036 Shares of Company Stock

Anixa Biosciences Inc (NASDAQ:ANIX) Director Lewis Titterton, Jr. acquired 49,036 shares of the stock in a transaction that occurred on Wednesday, September 23rd. The stock was acquired at an average cost of $2.69 per share, for a total transaction of $131,906.84. Following the completion of the purchase, the director owned 1,046,003 shares in the company, valued at $2,813,748.07. The trade was a 4.92% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Anixa Biosciences Stock Down 2.9%

Shares of ANIX traded down $0.08 during mid-day trading on Friday, reaching $2.70. 179,907 shares of the company’s stock were exchanged, compared to its average volume of 204,111. Anixa Biosciences Inc has a 52-week low of $2.32 and a 52-week high of $5.46. The company has a market cap of $93.85 million, a price-to-earnings ratio of -8.44 and a beta of 0.51. The company has a 50-day simple moving average of $3.25 and a two-hundred day simple moving average of $2.97.

Anixa Biosciences (NASDAQ:ANIX) last announced its earnings results on Wednesday, September 9th. The company reported ($0.08) EPS for the quarter, meeting analysts’ consensus estimates of ($0.08). As a group, equities research analysts predict that Anixa Biosciences Inc will post -0.31 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on ANIX shares. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research note on Tuesday, June 30th. Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 17th. HC Wainwright cut their price objective on shares of Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday. Citigroup reissued a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Finally, Zacks Research lowered shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 19th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $8.00.

Institutional Investors Weigh In On Anixa Biosciences

A number of institutional investors have recently bought and sold shares of ANIX. BlackRock Inc. purchased a new position in Anixa Biosciences during the second quarter worth approximately $559,000. GSA Capital Partners LLP purchased a new stake in shares of Anixa Biosciences during the 2nd quarter valued at $329,000. Renaissance Technologies LLC increased its holdings in shares of Anixa Biosciences by 13.6% during the 1st quarter. Renaissance Technologies LLC now owns 61,173 shares of the company’s stock worth $158,000 after buying an additional 7,300 shares during the last quarter. Kestra Advisory Services LLC increased its holdings in shares of Anixa Biosciences by 96.2% during the 1st quarter. Kestra Advisory Services LLC now owns 51,000 shares of the company’s stock worth $132,000 after buying an additional 25,000 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Anixa Biosciences in the 2nd quarter worth $133,000. 29.13% of the stock is currently owned by hedge funds and other institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. The company’s research programs are designed to use the immune system to prevent or treat serious illnesses.

Anixa’s cancer programs include vaccine approaches for ovarian cancer and triple-negative breast cancer, developed in collaboration with researchers at Cleveland Clinic. The company is also developing chimeric antigen receptor T-cell, or CAR-T, therapies intended to target cancer cells, including programs focused on ovarian cancer.

In addition to oncology, Anixa has pursued vaccine and therapeutic technologies for infectious diseases.